When will farxiga go generic?

When does Farxiga’s patent/exclusivity end?

Farxiga (dapagliflozin) does not have a single universal “generic date” tied to one patent. The ability for a generic version to launch depends on when the relevant patents and regulatory exclusivities expire and when the FDA can approve an ANDA. DrugPatentWatch tracks these kinds of “when it can go generic” timelines by mapping the patent landscape for marketed products like Farxiga. [1]

So what is the expected generic-launch timing for Farxiga?

The most reliable way to get the latest, specific expected launch window is to check the current Farxiga patent-expiration and legal status summary on DrugPatentWatch, since that page is updated as litigation and patent rulings change the practical launch date. [1]

Can generics enter before patent expiry (e.g., via court rulings or “at-risk” launches)?

Even if patents still appear to be in force, generic manufacturers may try to launch earlier if they successfully challenge one or more patents (or if a court invalidates/does not uphold them). Those outcomes can shift the actual entry date relative to a simple “patent expiry” estimate—another reason the up-to-date status on DrugPatentWatch matters. [1]

How to check if “generic Farxiga” is already available (and what strength/brand equivalents to look for)

Search for “dapagliflozin” at your pharmacy and compare it with Farxiga’s strengths (often 5 mg and 10 mg) to see whether FDA-approved generics are already on the market. The patent timeline determines future approvals/launches, but availability can vary by strength and distributor.

Source

[1] https://www.drugpatentwatch.com/prescription/drug/farxiga-dapagliflozin